- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05862896
Exploring Gas Transfer and the Utility of Dynamic Chest Radiography in Long Covid Patients (LoCTDC)
Exploring Gas Transfer and the Utility of Dynamic Chest Radiography in Long Covid Patients.
Study Overview
Status
Conditions
Detailed Description
Long COVID is the term used to describe patients who present with persistent symptoms after recovering from SARS-CoV-2 infection. Patients exhibit a range of symptoms and commonly report respiratory and cardiac phenomena including breathlessness, feeling tight chested and having persistent tachycardias. Survey data suggests up to 87% of patients discharged from hospital after COVID-19 infection have ongoing symptoms 60 days after discharge, with 43% describing breathlessness. In the USA, 35% of patients treated for SARS-CoV-2 as an outpatient have ongoing symptoms, with a similar percentage of the population unable to return to their normal work. The natural history and pathophysiology of long COVID is not yet fully understood. Few studies have explored pulmonary function in post-COVID patients. There are suggestions that functional limitation is related to lung abnormalities affecting both ventilation (air flow) and perfusion (blood flow), possibly caused by micro-blood clots. Establishing a relatively cost-effective and accessible way of diagnosing these will allow clinicians to treat or signpost the patients to the correct services. This is vital at both the patient and health system level.
Full pulmonary function testing is routinely done in respiratory clinics to investigate breathlessness and diagnose conditions such as asthma, chronic obstructive pulmonary disease (COPD) and pulmonary fibrosis. It includes a measure of transfer factor, an estimate of the efficiency of the diffusion of gas from the lung into the blood stream. The lungs' ability to absorb carbon monoxide (CO) is measured as a proxy for the ability to absorb oxygen. It is hypothesised that long COVID patients with breathlessness have abnormal gas transfer due to lung tissue damage at an alveolar level and/or perfusion abnormalities such as micro clots. Dynamic X-ray is a new, innovative technology to image the thoracic cavity throughout the breathing cycle allowing assessment of pulmonary function and possibly diagnose small ventilation-perfusion abnormities. Liverpool hosts the only dynamic X-ray machine in Europe. Potential applications beyond COVID are numerous, including filling diagnostic gaps in many lung diseases where expensive lung function testing is an unrealistic possibility in the medium term.
Study Type
Enrollment (Anticipated)
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Adults (over 18 years old)
- Patients with breathlessness (defined as self-reported modified Borg Scale score of 2 or more when walking on flat ground for 100 metres) that has continued or developed and persists more than 4 weeks after acute COVID 19 i.e., related to 'long COVID' (covid confirmed by photographic evidence of positive lateral flow/NHS application, EMIS records or hospital lab data).
- Able to achieve positioning for a PA chest X-ray for a 20 second period
- Able to hold their breath for at least 7 seconds
- Fluent spoken English - to ensure a comprehensive understanding of the research project and their proposed involvement
- Able to provide written informed consent
- For control group: Age, sex matched to participants identified in the affected group
Exclusion Criteria:
- Any contraindication to pulmonary function testing or DCR
- Pregnancy
- For women of childbearing age, a positive pregnancy test or refusal of pregnancy test (a negative urinary pregnancy test on the day of DCR is a requirement)
- Significant other respiratory co-morbidities as judged by study clinician
- Significant research related radiation exposure in last 12 months prior to consent (from participation in a previous studies involving radiation exposure, with a research dose constraint of 0.4 mSv)
- Unable to provide informed consent for any reason
- For the long covid arm no evidence of a positive covid-19 test
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
Control
Healthy, age and sex matched controls
|
Long Covid
Patients with breathlessness (defined as self-reported modified Borg Scale score of 2 or more when walking on flat ground for 100 metres) that has continued or developed and persists more than 4 weeks after acute COVID 19 i.e., related to 'long COVID' (covid confirmed by photographic evidence of positive lateral flow/NHS application, EMIS records or hospital lab data).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Primary objective
Time Frame: 12 months
|
1) To establish the proportion of patients with long COVID that have abnormal transfer factor on pulmonary function testing.
|
12 months
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- LHS0056
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COVID-19
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios Prevention SrlCompletedPost Acute Sequelae of COVID-19 | Post COVID-19 Condition | Long-COVID | Chronic COVID-19 SyndromeItaly
-
Yang I. PachankisActive, not recruitingCOVID-19 Respiratory Infection | COVID-19 Stress Syndrome | COVID-19 Vaccine Adverse Reaction | COVID-19-Associated Thromboembolism | COVID-19 Post-Intensive Care Syndrome | COVID-19-Associated StrokeChina
-
Massachusetts General HospitalRecruitingPost Acute COVID-19 Syndrome | Long COVID | Post Acute Sequelae of COVID-19 | Long COVID-19United States
-
Indonesia UniversityRecruitingPost-COVID-19 Syndrome | Long COVID | Post COVID-19 Condition | Post-COVID Syndrome | Long COVID-19Indonesia
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkNot yet recruitingPost-COVID-19 Syndrome | Long COVID | Long Covid19 | Post COVID-19 Condition | Post-COVID Syndrome | Post COVID-19 Condition, Unspecified | Post-COVID ConditionNetherlands
-
Dr. Soetomo General HospitalIndonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, IndonesiaRecruitingCOVID-19 Pandemic | COVID-19 Vaccines | COVID-19 Virus DiseaseIndonesia
-
University of Witten/HerdeckeInstitut für Rehabilitationsforschung NorderneyCompletedPost-COVID-19 Syndrome | Long-COVID-19 SyndromeGermany
-
Jonathann Kuo, MDActive, not recruitingSARS-CoV2 Infection | Post-COVID-19 Syndrome | Dysautonomia | Post Acute COVID-19 Syndrome | Long COVID | Long Covid19 | COVID-19 Recurrent | Post-Acute COVID-19 | Post-Acute COVID-19 Infection | Post Acute Sequelae of COVID-19 | Dysautonomia Like Disorder | Dysautonomia Orthostatic Hypotension Syndrome | Post... and other conditionsUnited States
-
University Hospital, Ioannina1st Division of Internal Medicine, University Hospital of IoanninaRecruitingCOVID-19 Pneumonia | COVID-19 Respiratory Infection | COVID-19 Pandemic | COVID-19 Acute Respiratory Distress Syndrome | COVID-19-Associated Pneumonia | COVID 19 Associated Coagulopathy | COVID-19 (Coronavirus Disease 2019) | COVID-19-Associated ThromboembolismGreece